1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Immune Response BioPharma, Inc. Logo

Immune Response BioPharma, Inc. Business Update Sees Blockbuster MS NeuroVax Partnership by Q1 2013

Immune Response BioPharma, Inc. Provides Business Update Sees Blockbuster MS Drug NeuroVax the Gold Standard of Care for MS and a Partnership by the end of Q1 2013

 
PRLog - Sep. 28, 2012 - Immune Response BioPharma, Inc. Provides Business Update Sees Blockbuster MS Drug NeuroVax the Gold Standard of Care for MS and Partnerships for NeuroVax & RAVAX by the end of Q1 2013.

Immune Response BioPharma, Inc. Today provides a business update for the drug discovery pipeline and sees partnerships for both NeuroVax for MS and RAVAX for RA by the end of Q1 2013. IRBP is currently in discussions with several big pharma potential partners and will select the best partner to help the company reach its goals of bringing to market the first Multiple Sclerosis Vaccine and the first Rheumatoid Arthritis Vaccine to market.

IRBP Financial Guidance through First Half of  2013

* Upfront Partnership Revenues $25-100 Million for NeuroVax for Multiple Sclerosis
  6-8% Royalty Rate

* Upfront Partnership Revenues $25-100 Million for RAVAX for Rheumatoid Arthritis
  6-8% Royalty Rate

* Cash Usage for the NeuroVax Phase 2B Study $10-15M

* Cash Usage for the RAVAX Phase 3 Study $25-30M

* Secure Big Pharma Partnerships for both NeuroVax and RAVAX total Study Costs $45M

* Sign CRO Contracts for both NeuroVax and RAVAX Studies by the end of Q1 2013

* Explore Licensing of RAVAX & NeuroVax in Additional Markets Japan & Korea

* Expecting Allowance from Canada for Auto-Immune Disease Patent

* Begin Manufacturing Planning for REMUNE with a Ramp up & Stock Piling of REMUNE
         and Prepare for FDA & EMA NDA Emergency Filings Cost $2-4M

* First Year REMUNE Revenues Estimated North of $1 Billion World Wide upon
  successful Regulatory Filing Approval and Manufacturing & Stock Piling

* Capital Raising: Financing Equity and or  Debt  up to $150M

IRBP has all three of its late stage vaccines for MS, RA and AIDS on track and now has positioned the company for growth with a solid plan of action to achieve its results by partnering with the right big pharma partners who have the same goals we have which are to drive revenues and profitability while helping society by treating unmet diseases worldwide.

"We are preparing for the success of IRBP by partnering with the right big pharma partners who have the same or similar goals we do of being the market leader in vaccine development and technology in rare auto-immune diseases. We are in active discussions with several big pharma companies and we look to complete a corporate partnership sooner rather than later. I am even more confident that we will strike a fair partnership for our flagship drug NeuroVax for MS and our other blockbuster drug for RA, RAVAX. I am proud of our team as we have worked together to build a world class company with a rich and deep pipeline unrivaled by any other biotech or pharma world wide. We believe NeuroVax will become the gold standard of care for MS and treatment of choice" Mr. Buswell CEO of IRBP.

Immune Response BioPharma, Inc. Maybe Found on the World Wide Web @ www.immuneresponse.net

--- End ---

Click to Share

Contact Email:
***@immuneresponsebiopharma.com Email Verified
Source:Immune Response BioPharma, Inc.
Phone:(917) 275-7931
Zip:10001
City/Town:New York City - New York - United States
Industry:Biotech, Health
Tags:immune response biopharma, NeuroVax, hiv aids, therapeutic vaccines, MS multiple sclerosis
Last Updated:Jan 08, 2013
Shortcut:prlog.org/11986297
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share